elzonris
Generic: tagraxofusp-erzs
elzonris: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| STEMLINE THERAPEUTICS INC (STML) | Approved |
FDA Decisions
Approval1 INDICATIONS AND USAGE ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older ( 1 )(STML)
Frequently asked questions
Who is developing elzonris?
elzonris is being developed by STEMLINE THERAPEUTICS INC.
What is elzonris's latest FDA decision?
The most recent tracked FDA decision for elzonris is Approval for 1 INDICATIONS AND USAGE ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older ( 1 ), dated December 21, 2018.
Get deeper analysis on elzonris
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis